Publications by authors named "Bea Parcutela"
J Hematol Oncol
August 2024
Article Synopsis
- IL1RAP is selectively expressed on AML cells and leukemic stem cells, making it a promising target for treatment without affecting normal blood stem cells.
- BIF002, a novel anti-IL1RAP/CD3 T cell engager, showed strong anti-leukemic effects in laboratory tests and patient samples, significantly activating T cells and leading to the destruction of AML cells.
- In animal models, BIF002 demonstrated a marked reduction in leukemic cells and extended survival rates, with no observable safety issues, indicating its potential effectiveness in treating AML.
